Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients.

Ishitobi M, Shibuya K, Komoike Y, Koyama H, Inaji H.

Patient Prefer Adherence. 2013 Nov 22;7:1201-6. doi: 10.2147/PPA.S52687. eCollection 2013.

2.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
3.

Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy.

Mastroianni CM, Viscomi C, Ceniti S, De Simone R, Filice A, Gadaleta Caldarola G, Infusino S, Manfredi C, Rea A, Sandomenico C, Turano S, Serranò F, Condemi G, Cortese C, Prantera T, Palazzo S; Gruppo Oncologico Calabrese Multidisciplinare (GOCaM).

Patient. 2008 Jul 1;1(3):181-7. doi: 10.2165/1312067-200801030-00005.

PMID:
22272925
6.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
7.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
8.

Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?

Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ.

Ann Oncol. 2005 Nov;16(11):1786-94. Epub 2005 Aug 26.

9.

Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.

Duric VM, Butow PN, Sharpe L, Boyle F, Beith J, Wilcken NR, Heritier S, Coates AS, John Simes R, Stockler MR.

Psychooncology. 2007 Jan;16(1):48-59.

PMID:
16856128
10.

Discrepancy between preference and actual adjuvant therapy for breast cancer.

Wood ME, Fama TA, Ashikaga T, Muss HB.

Clin Breast Cancer. 2010 Oct 1;10(5):398-403. doi: 10.3816/CBC.2010.n.053.

PMID:
20920985
11.

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.

Lindley C, Vasa S, Sawyer WT, Winer EP.

J Clin Oncol. 1998 Apr;16(4):1380-7.

PMID:
9552041
12.

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN.

Breast J. 2002 Jan-Feb;8(1):2-9.

PMID:
11856154
13.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24. Review.

PMID:
15107948
14.

Patient preferences for oral versus intravenous palliative chemotherapy.

Liu G, Franssen E, Fitch MI, Warner E.

J Clin Oncol. 1997 Jan;15(1):110-5.

PMID:
8996131
15.

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.

Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.

Cancer. 2012 Apr 15;118(8):1982-8. doi: 10.1002/cncr.26484. Epub 2011 Sep 1.

16.

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.

Vardy J, Pond G, Dodd A, Warr D, Seruga B, Clemons M, Bordeleau L, Goodwin P, Tannock IF.

Breast Cancer Res Treat. 2012 Nov;136(1):143-51. doi: 10.1007/s10549-012-2205-3. Epub 2012 Sep 6.

PMID:
22956006
17.
18.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

19.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
20.
Items per page

Supplemental Content

Write to the Help Desk